A comparison on efficacy of different doses of aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia

Objective To explore the efficacy and safety of different doses of aripiprazole on hyperprolactinemia caused by risperidone in female patients with schizophrenia.Methods 60 cases of female schizophrenic patients with hyperprolactinemia induced by risperidone were randomly divided into aripiprazole 5mg / d(group A) and 10mg / d(group B) treatment group with 30 cases in each group,the original risperidone in treatment of plan unchanged for 12 weeks,the blood prolactin level was measured at the baseline and at the end of 12th week,at the same time clinical symptoms and adverse reaction were assessed with the Brief psychiatric rating scale(BPRS) and the treatment emergene symptoms scale(TESS).Results ①The 12 weeks after treatment,the A,B serum prolactin levels in two groups were decreased,and the difference was statistically significant(t = 27.63,P 0.01;t = 26.26,P 0.01).there was no significant difference between the two groups(t = 1.36,P = 0.18) ② There was no significant changes on the total scores of BPRS before and after treatment in the two groups(t = 1.86,P = 0.07;t = 1.80,P = 0.08).③Adverse reactions of two groups show no significant difference(χ2= 0.12,P = 0.73).Conclusion Aripiprazole(5mg / d、10mg / d) is effective and safe on hyperprolactinemia caused by risperidone in female patients with schizophrenia,and the efficacy among two groups are equivalent.